Stuttgart - Delayed Quote EUR

ABIONYX Pharma SA (609.SG)

Compare
1.2200
+0.0040
+(0.33%)
At close: January 10 at 3:37:14 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,640.0000
4,640.0000
5,252.0000
675.0000
--
Cost of Revenue
4,022.0000
4,022.0000
4,616.0000
416.0000
--
Gross Profit
618.0000
618.0000
636.0000
259.0000
--
Operating Expense
3,783.0000
3,783.0000
4,612.0000
6,128.0000
2,880.0000
Operating Income
-3,165.0000
-3,165.0000
-3,976.0000
-5,869.0000
-2,880.0000
Net Non Operating Interest Income Expense
-66.0000
-66.0000
-136.0000
148.0000
1,043.0000
Pretax Income
-3,518.0000
-3,518.0000
-4,206.0000
-5,822.0000
-1,886.0000
Net Income Common Stockholders
-3,518.0000
-3,518.0000
-4,206.0000
-5,822.0000
-1,886.0000
Diluted NI Available to Com Stockholders
-3,518.0000
-3,518.0000
-4,206.0000
-5,822.0000
-1,886.0000
Basic EPS
-0.11
-0.11
-0.15
-0.23
-0.08
Diluted EPS
-0.11
-0.11
-0.15
-0.23
-0.08
Basic Average Shares
32,191.6330
32,191.6330
27,967.0140
24,879.8580
22,508.3020
Diluted Average Shares
32,191.6330
32,191.6330
29,859.8110
25,918.5050
23,488.3000
Total Operating Income as Reported
-3,412.0000
-3,412.0000
-4,109.0000
-5,952.0000
-2,968.0000
Total Expenses
7,805.0000
7,805.0000
9,228.0000
6,544.0000
2,880.0000
Net Income from Continuing & Discontinued Operation
-3,518.0000
-3,518.0000
-4,206.0000
-5,822.0000
-1,886.0000
Normalized Income
-3,271.0000
-3,271.0000
-4,073.0000
-5,739.0000
-1,798.0000
Interest Income
60.0000
60.0000
6.0000
4.0000
55.0000
Interest Expense
19.0000
19.0000
61.0000
8.0000
--
Net Interest Income
-66.0000
-66.0000
-136.0000
148.0000
1,043.0000
EBIT
-3,499.0000
-3,499.0000
-4,145.0000
-5,814.0000
-1,886.0000
EBITDA
-3,346.0000
-3,346.0000
-4,010.0000
-5,695.0000
-1,864.0000
Reconciled Cost of Revenue
4,022.0000
4,022.0000
4,616.0000
416.0000
--
Reconciled Depreciation
153.0000
153.0000
135.0000
119.0000
22.0000
Net Income from Continuing Operation Net Minority Interest
-3,518.0000
-3,518.0000
-4,206.0000
-5,822.0000
-1,886.0000
Total Unusual Items Excluding Goodwill
-247.0000
-247.0000
-133.0000
-83.0000
-88.0000
Total Unusual Items
-247.0000
-247.0000
-133.0000
-83.0000
-88.0000
Normalized EBITDA
-3,099.0000
-3,099.0000
-3,877.0000
-5,612.0000
-1,776.0000
12/31/2020 - 8/28/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PI3.SG Gubra AS
89.80
-1.97%
 
PI3.DU Gubra AS
89.80
-0.44%
 
NAMSW NewAmsterdam Pharma Company N.V.
14.78
+3.50%
 
POLB.L Poolbeg Pharma PLC
5.15
-8.04%
 
SNGX Soligenix, Inc.
3.2000
-2.14%
 
GUBRA.CO Gubra A/S
666.00
-1.48%
 
AUTL Autolus Therapeutics plc
2.3600
-2.07%
 
ZYME Zymeworks Inc.
13.22
-6.44%
 
CVM CEL-SCI Corporation
0.4252
+16.05%
 
MAIA MAIA Biotechnology, Inc.
2.1200
-0.47%